Barriers and Facilitators to Community Pharmacist-Provided Injectable Naltrexone for Formerly Incarcerated Individuals During Community Reentry in Wisconsin

Jason Scott Chladek, Michelle A Chui
{"title":"Barriers and Facilitators to Community Pharmacist-Provided Injectable Naltrexone for Formerly Incarcerated Individuals During Community Reentry in Wisconsin","authors":"Jason Scott Chladek, Michelle A Chui","doi":"10.1101/2024.09.13.24313637","DOIUrl":null,"url":null,"abstract":"Medications for opioid use disorder (MOUD), including injectable naltrexone, are a key component in the treatment of opioid use disorder (OUD). These medications are especially important for individuals transitioning out of correctional facilities and back into their communities, as individuals receiving MOUD are 85% less likely to die due to drug overdose in the first month post-release and have a 32% lower risk of rearrest. Unfortunately, few formerly incarcerated individuals have access to MOUD upon reentry, incurring a 40-fold greater likelihood of overdose following release compared to the general population. While 84% of Wisconsin jails offering MOUD offer naltrexone, less than half provide linkage to community treatment for reentering individuals. In Wisconsin, community pharmacists have the authority to provide naltrexone injections. However, they have not been explored as a resource for improving access to this medication for formerly incarcerated individuals. As a first step, the goal of this study was to understand the barriers and facilitators impacting access to community pharmacist-provided injectable naltrexone for this patient population during community reentry period. The researcher conducted semi-structured interviews with 18 individuals representing five stakeholder groups. Deductive and inductive content analysis were used to identify barrier and facilitator categories across the five levels of the Socioecological Model. Overall, participants discussed factors at every level, and many barriers and facilitators confirmed findings from existing literature focused on MOUD access for formerly incarcerated individuals. Participants also identified factors more specific to community pharmacies, including 1) lack of interagency collaboration between pharmacists, prescribers, and correctional facilities and 2) lack of awareness of community pharmacist-provided MOUD services. Future research should explore interventions to address the barriers identified in this study and improve connections between community pharmacists and formerly incarcerated individuals. This work can help ensure that these individuals are given the chance to successfully reintegrate into society.","PeriodicalId":501282,"journal":{"name":"medRxiv - Addiction Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Addiction Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.13.24313637","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Medications for opioid use disorder (MOUD), including injectable naltrexone, are a key component in the treatment of opioid use disorder (OUD). These medications are especially important for individuals transitioning out of correctional facilities and back into their communities, as individuals receiving MOUD are 85% less likely to die due to drug overdose in the first month post-release and have a 32% lower risk of rearrest. Unfortunately, few formerly incarcerated individuals have access to MOUD upon reentry, incurring a 40-fold greater likelihood of overdose following release compared to the general population. While 84% of Wisconsin jails offering MOUD offer naltrexone, less than half provide linkage to community treatment for reentering individuals. In Wisconsin, community pharmacists have the authority to provide naltrexone injections. However, they have not been explored as a resource for improving access to this medication for formerly incarcerated individuals. As a first step, the goal of this study was to understand the barriers and facilitators impacting access to community pharmacist-provided injectable naltrexone for this patient population during community reentry period. The researcher conducted semi-structured interviews with 18 individuals representing five stakeholder groups. Deductive and inductive content analysis were used to identify barrier and facilitator categories across the five levels of the Socioecological Model. Overall, participants discussed factors at every level, and many barriers and facilitators confirmed findings from existing literature focused on MOUD access for formerly incarcerated individuals. Participants also identified factors more specific to community pharmacies, including 1) lack of interagency collaboration between pharmacists, prescribers, and correctional facilities and 2) lack of awareness of community pharmacist-provided MOUD services. Future research should explore interventions to address the barriers identified in this study and improve connections between community pharmacists and formerly incarcerated individuals. This work can help ensure that these individuals are given the chance to successfully reintegrate into society.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
威斯康星州由社区药剂师为重返社区的刑满释放人员提供注射用纳曲酮的障碍和促进因素
包括注射用纳曲酮在内的阿片类药物使用障碍 (MOUD) 药物是治疗阿片类药物使用障碍 (OUD) 的关键组成部分。接受 MOUD 治疗的人在释放后的第一个月内因吸毒过量死亡的可能性降低 85%,再次被逮捕的风险降低 32%。遗憾的是,很少有曾经被监禁的人在重返社会时能够获得 MOUD,他们在获释后因吸毒过量而死亡的可能性是普通人的 40 倍。虽然威斯康星州 84% 提供 MOUD 的监狱提供纳曲酮,但只有不到一半的监狱为重新入狱者提供社区治疗链接。在威斯康星州,社区药剂师有权提供纳曲酮注射。然而,社区药剂师尚未被视为改善前囚犯获得这种药物的资源。作为第一步,本研究的目标是了解影响该患者群体在重返社区期间获得社区药剂师提供的注射用纳曲酮的障碍和促进因素。研究人员对代表五个利益相关群体的 18 名个人进行了半结构化访谈。通过演绎和归纳内容分析,确定了社会生态模型五个层次中的障碍和促进因素类别。总体而言,参与者讨论了各个层面的因素,许多障碍和促进因素证实了现有文献中关于前囚犯获得谅解备忘录的研究结果。与会者还指出了一些社区药房特有的因素,包括:1)药剂师、处方医生和惩教机构之间缺乏机构间合作;2)缺乏对社区药剂师提供的 MOUD 服务的认识。未来的研究应探索干预措施,以解决本研究中发现的障碍,并改善社区药剂师与曾被监禁者之间的联系。这项工作有助于确保这些人有机会成功重返社会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
National trends in drug overdose mortality in Asian American, Native Hawaiian, and Pacific Islander populations, 2018-2022 Transcranial magnetic stimulation of dorsomedial prefrontal cortex for cocaine use disorder: A pilot study Diagnostic Validity of Drinking Behaviour for Identifying Alcohol Use Disorder: Findings from a Nationally Representative Sample of Community Adults and an Inpatient Clinical Sample Barriers and Facilitators to Community Pharmacist-Provided Injectable Naltrexone for Formerly Incarcerated Individuals During Community Reentry in Wisconsin Overdoses with Xylazine and Fentanyl Recorded in Pennsylvania’s Overdose Information Network
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1